Literature DB >> 15860927

Myosin loss in denervated rat soleus muscle after dexamethasone treatment.

Hideo Horinouchi1, Toshihide Kumamoto, Noriyuki Kimura, Hidetsugu Ueyama, Tomiyasu Tsuda.   

Abstract

OBJECTIVE: Critical illness myopathy (CIM) is an acute myopathy that appears in the setting of critical illness or during exposure to corticosteroids and neuromuscular blocking agents. Its pathological feature is selective loss of thick myosin filaments. Our aim is to gain further insight into the pathomechanism of myosin loss in this myopathy.
METHODS: To clarify the expression of myosin heavy chain (MHC) and ubiquitin ligase atrogin-1 in this myopathy, histological, immunohistochemical, SDS-PAGE, and semiquantitative reverse transcriptase-polymerase chain reaction studies were performed on innervated and denervated rat soleus muscles after saline and dexamethasone treatments.
RESULTS: Denervated muscles from dexamethasone-treated rats showed marked MHC loss. The mRNA expression of ubiquitin ligase atrogin-1 was significantly increased in denervated dexamethasone-treated muscles, suggesting that the ubiquitin-proteasome pathway plays an important role in muscular wasting in CIM. Furthermore, mRNA levels of MHC I, a myosin isoform, were decreased in the denervated dexamethasone-treated muscles.
CONCLUSION: Our findings suggest that an altered transcription rate of myosin, as well as the upregulation of multiple ubiquitin ligases, may be responsible for selective myosin loss in this myopathy. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15860927     DOI: 10.1159/000084113

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  11 in total

1.  Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle.

Authors:  Michael L Paffett; Selita N Lucas; Matthew J Campen
Journal:  Vascul Pharmacol       Date:  2011-11-25       Impact factor: 5.773

2.  C. elegans RNAi space experiment (CERISE) in Japanese Experiment Module KIBO.

Authors:  Atsushi Higashitani; Toko Hashizume; Tomoko Sugimoto; Chihiro Mori; Kanako Nemoto; Timothy Etheridge; Nahoko Higashitani; Takako Takanami; Hiromi Suzuki; Keiji Fukui; Takashi Yamazaki; Noriaki Ishioka; Nathaniel Szewczyk; Akira Higashibata
Journal:  Biol Sci Space       Date:  2009-10-01

3.  IL-1α reversibly inhibits skeletal muscle ryanodine receptor. a novel mechanism for critical illness myopathy?

Authors:  Oliver Friedrich; Bing Yi; Joshua N Edwards; Barbara Reischl; Anette Wirth-Hücking; Andreas Buttgereit; Roland Lang; Cornelia Weber; Fabian Polyak; Ilon Liu; Frederic von Wegner; Tanya R Cully; Aven Lee; Patrick Most; Mirko Völkers
Journal:  Am J Respir Cell Mol Biol       Date:  2014-06       Impact factor: 6.914

Review 4.  Steroid myopathy: some unresolved issues.

Authors:  M A Minetto; F Lanfranco; G Motta; S Allasia; E Arvat; G D'Antona
Journal:  J Endocrinol Invest       Date:  2011-05       Impact factor: 4.256

5.  Risk factors for physical impairment after acute lung injury in a national, multicenter study.

Authors:  Dale M Needham; Amy W Wozniak; Catherine L Hough; Peter E Morris; Victor D Dinglas; James C Jackson; Pedro A Mendez-Tellez; Carl Shanholtz; E Wesley Ely; Elizabeth Colantuoni; Ramona O Hopkins
Journal:  Am J Respir Crit Care Med       Date:  2014-05-15       Impact factor: 21.405

Review 6.  Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications.

Authors:  G Arnaldi; T Mancini; G Tirabassi; L Trementino; M Boscaro
Journal:  J Endocrinol Invest       Date:  2012-04       Impact factor: 4.256

7.  Impact of post-synaptic block of neuromuscular transmission, muscle unloading and mechanical ventilation on skeletal muscle protein and mRNA expression.

Authors:  H Norman; J Nordquist; P Andersson; T Ansved; X Tang; B Dworkin; L Larsson
Journal:  Pflugers Arch       Date:  2006-07-26       Impact factor: 3.657

Review 8.  [Critical illness myopathy in intensive care patients. Pathogenetic concepts and clinical management].

Authors:  O Friedrich; E Hund
Journal:  Anaesthesist       Date:  2006-12       Impact factor: 1.041

9.  Enhanced muscle shortening and impaired Ca2+ channel function in an acute septic myopathy model.

Authors:  Oliver Friedrich; Ernst Hund; Frederic von Wegner
Journal:  J Neurol       Date:  2009-11-04       Impact factor: 4.849

10.  Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS.

Authors:  Catherine L Hough; Kenneth P Steinberg; B Taylor Thompson; Gordon D Rubenfeld; Leonard D Hudson
Journal:  Intensive Care Med       Date:  2008-10-23       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.